The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study.

Author(s): Mersereau JE, Khouri C, Jaffe RB

Affiliation(s): Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California, USA. jmerse@med.unc.edu

Publication date & source: 2010-08, Fertil Steril., 94(3):1138-40. Epub 2010 Jan 8.

Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Compared with placebo, alendronate treatment resulted in a significant protection against bone loss in healthy perimenopausal women. This protection occurred at both the spine and the hip and was evident after 6 months of therapy. Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.